DOCSLIB.ORG

Protein Kinase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Flexi® ORF Clone www.promega.co.jp/flexiclone/ Protein Kinase 456個 （2013/1/24 現在） 遺伝子シンボル 説明 FXC_PID 価格 FHC_PID 価格 AAK1 AP2 associated kinase 1 FXC00722 40,000 FHC00722 50,000 AATK apoptosis-associated tyrosine kinase FXC04004 40,000 FHC04004M 60,000 ABL1 c-abl oncogene 1, receptor tyrosine kinase FXC01406 40,000 FHC01406 50,000 AC008735.15 Putative uncharacterized serine/threonine-protein kinase SgK110FXC11098M 50,000 FHC11098 50,000 AC087465.1 Pseudopodium-enriched atypical kinase 1 FXC12507M 50,000 FHC12507 50,000 ACTR2 ARP2 actin-related protein 2 homolog (yeast) FXC02146 40,000 FHC02146 50,000 ACVR1 Activin receptor type-1 Precursor (EC 2.7.11.30)(Activin receptor typeFXC03971 I)(ACTR-I)(Serine/threonine-protein40,000 FHC03971 kinase50,000 receptor R1)(SKR1)(Activin receptor-like kinase 2)(ALK-2)(TGF-B superfamily receptor type I)(TSR-I) ACVR1B activin A receptor, type IB FXC01408 40,000 FHC01408 50,000 ACVR1C activin A receptor, type IC FXC09109M 50,000 FHC09109 50,000 ACVR2A activin A receptor, type IIA FXC11423 40,000 FHC11423 50,000 ACVR2B activin A receptor, type IIB FXC11748M 50,000 FHC11748 50,000 ACVRL1 activin A receptor type II-like 1, transcript variant 1 FXC28135M 50,000 FHC28135 50,000 ADCK1 Uncharacterized aarF domain-containing protein kinase 1 PrecursorFXC03544 (EC 2.7.11.-) 40,000 FHC03544 50,000 ADCK2 aarF domain containing kinase 2 FXC23115M 50,000 FHC23115 50,000 ADCK3 aarF domain containing kinase 3 FXC20844M 50,000 FHC20844 50,000 ADCK4 aarF domain containing kinase 4 FXC09210M 50,000 FHC09210 50,000 ADCK5 aarF domain containing kinase 5 FXC11426 40,000 FHC11426 50,000 ADRBK1 adrenergic, beta, receptor kinase 1 FXC09648M 50,000 FHC09648 50,000 ADRBK2 adrenergic, beta, receptor kinase 2 FXC27231M 50,000 FHC27231 50,000 AKT1 v-akt murine thymoma viral oncogene homolog 1 FXC02215 40,000 FHC02215 50,000 AKT2 v-akt murine thymoma viral oncogene homolog 2 FXC26633 40,000 FHC26633 50,000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B,FXC02812 gamma) 40,000 FHC02812 50,000 ALK anaplastic lymphoma receptor tyrosine kinase FXC00337 40,000 FHC00337 50,000 ALPK2 alpha-kinase 2 FXC26314M 50,000 FHC26314 50,000 AMHR2 anti-Mullerian hormone receptor, type II FXC24752M 50,000 FHC24752 50,000 ANKK1 ankyrin repeat and kinase domain containing 1 FXC30508M 50,000 FHC30508 50,000 ARAF A-Raf proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1)(A-raf-1)(Proto-oncogeneFXC08066 40,000 Pks)FHC08066 50,000 ATR ataxia telangiectasia and Rad3 related FXC11858M 50,000 FHC11858 50,000 AURKA aurora kinase A FXC02742 40,000 FHC02742 50,000 AURKB Serine/threonine-protein kinase 12 (EC 2.7.11.1)(Aurora-B)(Aurora-FXC03950 and Ipl1-like midbody-associated40,000 FHC03950 protein 1)(AIM-1)(Aurora/IPL1-related50,000 kinase 2)(Aurora-related kinase 2)(STK-1) AURKC aurora kinase C FXC11256 40,000 FHC11256 50,000 AXL AXL receptor tyrosine kinase FXC01861 40,000 FHC01861 50,000 BCKDK [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrialFXC10381 Precursor40,000 (EC 2.7.11.4)(Branched-chainFHC10381 50,000 alpha-ketoacid dehydrogenase kinase)(BCKD-kinase)(BCKDHKIN) BCR breakpoint cluster region FXC00975 40,000 FHC00975 50,000 BLK Tyrosine-protein kinase BLK (EC 2.7.10.2)(B lymphocyte kinase)(p55-BLK)FXC03808 40,000 FHC03808 50,000 BMPR1A bone morphogenetic protein receptor, type IA FXC09257 40,000 FHC09257 50,000 BMPR1B Bone morphogenetic protein receptor type-1B Precursor (EC 2.7.11.30)(CDw293FXC03435 antigen)40,000 FHC03435 50,000 BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase)FXC01318 40,000 FHC01318 50,000 BMX BMX non-receptor tyrosine kinase FXC08849 40,000 FHC08849 50,000 BRAF B-Raf proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1)(p94)(v-RafFXC11883 murine40,000 sarcomaFHC11883 viral oncogene homolog50,000 B1) BRSK2 BR serine/threonine kinase 2 FXC29626M 50,000 FHC29626 50,000 BTK Tyrosine-protein kinase BTK (EC 2.7.10.2)(Bruton tyrosine kinase)(AgammaglobulinaemiaFXC05404M 50,000 tyrosineFHC05404 kinase)(ATK)(B-cell50,000 progenitor kinase)(BPK) BUB1B budding uninhibited by benzimidazoles 1 homolog beta (yeast) FXC01224 40,000 FHC01224 50,000 CAMK1 calcium/calmodulin-dependent protein kinase I FXC11206 40,000 FHC11206 50,000 CAMK1D calcium/calmodulin-dependent protein kinase ID FXC11216 40,000 FHC11216 50,000 CAMK2A calcium/calmodulin-dependent protein kinase II alpha FXC00158 40,000 FHC00158 50,000 CAMK2B calcium/calmodulin-dependent protein kinase II beta FXC04424 40,000 FHC04424 50,000 CAMK2D calcium/calmodulin-dependent protein kinase II delta FXC01765 40,000 FHC01765 50,000 CAMK2G calcium/calmodulin-dependent protein kinase II gamma FXC10307M 50,000 FHC10307 50,000 CAMK4 calcium/calmodulin-dependent protein kinase IV FXC11417 40,000 FHC11417 50,000 CAMKK1 calcium/calmodulin-dependent protein kinase kinase 1, alpha FXC10271M 50,000 FHC10271 50,000 CAMKK2 calcium/calmodulin-dependent protein kinase kinase 2, beta FXC09184M 50,000 FHC09184 50,000 CAMKV CaM kinase-like vesicle-associated FXC07876M 50,000 FHC07876 50,000 CASK Peripheral plasma membrane protein CASK (hCASK)(EC 2.7.11.1)(Calcium/calmodulin-dependentFXC04437M 50,000 FHC04437 serine protein50,000 kinase)(Lin-2 homolog) CDC2 cyclin-dependent kinase 1 FXC23867 40,000 FHC23867 50,000 CDC2L6 cell division cycle 2-like 6 (CDK8-like) FXC01935 40,000 FHC01935 50,000 CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) FXC01284 40,000 FHC01284 50,000 プロメガ株式会社 TEL. 03-3669-7981 納期はProduct ID (PID)が赤色のものは約2ヶ月、その他は約２週間です。 Flexi® ORF Clone www.promega.co.jp/flexiclone/ CDC42BPB CDC42 binding protein kinase beta (DMPK-like) FXC00181 40,000 FHC00181 50,000 CDC42BPG CDC42 binding protein kinase gamma (DMPK-like) FXC12645M 50,000 FHC12645 50,000 CDC7 cell division cycle 7 homolog (S. cerevisiae) FXC10990M 50,000 FHC10990 50,000 CDK10 cyclin-dependent kinase 10 FXC02837 40,000 FHC02837 50,000 CDK11A cyclin-dependent kinase 11A FXC11114M 50,000 FHC11114 50,000 CDK11A cyclin-dependent kinase 11A FXC12638M 50,000 FHC12638 50,000 CDK12 Cdc2-related kinase, arginine/serine-rich FXC02002 40,000 FHC02002 50,000 CDK12 cyclin-dependent kinase 12, transcript variant 1 FXC25993M 50,000 FHC25993 50,000 CDK13 cyclin-dependent kinase 13 FXC12636M 50,000 FHC12636 50,000 CDK15 cyclin-dependent kinase 15 FXC11569M 50,000 FHC11569 50,000 CDK17 cyclin-dependent kinase 17, transcript variant 1 FXC09466M 50,000 FHC09466 50,000 CDK2 cyclin-dependent kinase 2 FXC02738 40,000 FHC02738 50,000 CDK20 cyclin-dependent kinase 20, transcript variant 3 FXC23550M 50,000 FHC23550 50,000 CDK3 Cell division protein kinase 3 (EC 2.7.11.22) FXC03928 40,000 FHC03928 50,000 CDK4 Cell division protein kinase 4 (EC 2.7.11.22)(Cyclin-dependent kinaseFXC08159 4)(PSK-J3) 40,000 FHC08159 50,000 CDK5 cyclin-dependent kinase 5 FXC02662 40,000 FHC02662 50,000 CDK6 cyclin-dependent kinase 6 FXC10565 40,000 FHC10565 50,000 CDK7 cyclin-dependent kinase 7 FXC01723 40,000 FHC01723 50,000 CDK8 cyclin-dependent kinase 8 FXC24966M 50,000 FHC24966 50,000 CDK9 cyclin-dependent kinase 9 FXC08042M 50,000 FHC08042 50,000 CDKL1 cyclin-dependent kinase-like 1 (CDC2-related kinase) FXC25164M 50,000 FHC25164 50,000 CDKL2 cyclin-dependent kinase-like 2 (CDC2-related kinase) FXC21962M 50,000 FHC21962 50,000 CDKL3 cyclin-dependent kinase-like 3, transcript variant 1 FXC31101M 50,000 FHC31101 50,000 CDKL4 cyclin-dependent kinase-like 4 FXC28701M 50,000 FHC28701 50,000 CDKL5 cyclin-dependent kinase-like 5 FXC10738 40,000 FHC10738 50,000 CHEK1 Serine/threonine-protein kinase Chk1 (EC 2.7.11.1) FXC03424 40,000 FHC03424 50,000 CHEK2 Serine/threonine-protein kinase Chk2 (EC 2.7.11.1)(Cds1) FXC04554 40,000 FHC04554 50,000 CHUK conserved helix-loop-helix ubiquitous kinase FXC10858M 50,000 FHC10858 50,000 CIT citron (rho-interacting, serine/threonine kinase 21) FXC00156 40,000 FHC00156 50,000 CLK1 Dual specificity protein kinase CLK1 (EC 2.7.12.1)(CDC-like kinaseFXC01814 1) 40,000 FHC01814 50,000 CLK2 CDC-like kinase 2 FXC11421 40,000 FHC11421 50,000 CPNE3 copine III FXC00583 40,000 FHC00583 50,000 CSF1R colony stimulating factor 1 receptor FXC10479 40,000 FHC10479 50,000 CSK Tyrosine-protein kinase CSK (EC 2.7.10.2)(C-SRC kinase)(Protein-tyrosineFXC03488 kinase CYL)40,000 FHC03488 50,000 CSNK1A1 casein kinase 1, alpha 1 FXC01538 40,000 FHC01538 50,000 CSNK1A1L casein kinase 1, alpha 1-like FXC09266 40,000 FHC09266 50,000 CSNK1D Casein kinase I isoform delta (CKI-delta)(CKId)(EC 2.7.11.1) FXC03511 40,000 FHC03511 50,000 CSNK1E casein kinase 1, epsilon FXC01335 40,000 FHC01335 50,000 CSNK1G1 casein kinase 1, gamma 1 FXC11258 40,000 FHC11258 50,000 CSNK1G2 casein kinase 1, gamma 2 FXC11254 40,000 FHC11254 50,000 CSNK1G3 Casein kinase I isoform gamma-3 (CKI-gamma 3)(EC 2.7.11.1) FXC10431 40,000 FHC10431 50,000 CSNK2A1 casein kinase 2, alpha 1 polypeptide FXC08568M 50,000 FHC08568 50,000 CSNK2A2 casein kinase 2, alpha prime polypeptide FXC04660 40,000 FHC04660 50,000 DAPK1 death-associated protein kinase 1 FXC01854 40,000 FHC01854 50,000 DAPK2 death-associated protein kinase 2 FXC25418M 50,000 FHC25418 50,000 DAPK3 death-associated protein kinase 3 FXC26400M 50,000 FHC26400 50,000 DCLK1 doublecortin-like kinase 1 FXC00061 40,000 FHC00061 50,000 DCLK2 doublecortin-like kinase 2 FXC01748 40,000 FHC01748 50,000 DCLK3 doublecortin-like kinase 3 FXC12702M 50,000 FHC12702 50,000 DDR1 discoidin domain receptor tyrosine kinase 1 FXC02069 40,000 FHC02069 50,000 DMPK dystrophia myotonica-protein kinase FXC01383 40,000 FHC01383 50,000 DYRK1B dual-specificity tyrosine-(Y)-phosphorylation
Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB

    Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB

    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
  • ACVR1 Antibody Cat

    ACVR1 Antibody Cat

    ACVR1 Antibody Cat. No.: 4791 Western blot analysis of ACVR1 in A549 cell lysate with ACVR1 antibody at 1 μg/mL in (A) the absence and (B) the presence of blocking peptide. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human, Mouse HOMOLOGY: Predicted species reactivity based on immunogen sequence: Bovine: (100%), Rat: (93%) ACVR1 antibody was raised against a 14 amino acid synthetic peptide near the amino terminus of the human ACVR1. IMMUNOGEN: The immunogen is located within the first 50 amino acids of ACVR1. TESTED APPLICATIONS: ELISA, WB ACVR1 antibody can be used for detection of ACVR1 by Western blot at 1 μg/mL. APPLICATIONS: Antibody validated: Western Blot in human samples. All other applications and species not yet tested. At least four isoforms of ACVR1 are known to exist. This antibody is predicted to have no SPECIFICITY: cross-reactivity to ACVR1B or ACVR1C. POSITIVE CONTROL: 1) Cat. No. 1203 - A549 Cell Lysate Properties October 1, 2021 1 https://www.prosci-inc.com/acvr1-antibody-4791.html PURIFICATION: ACVR1 Antibody is affinity chromatography purified via peptide column. CLONALITY: Polyclonal ISOTYPE: IgG CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: ACVR1 Antibody is supplied in PBS containing 0.02% sodium azide. CONCENTRATION: 1 mg/mL ACVR1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one STORAGE CONDITIONS: year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: ACVR1 ACVR1 Antibody: FOP, ALK2, SKR1, TSRI, ACTRI, ACVR1A, ACVRLK2, Activin receptor type-1, ALTERNATE NAMES: Activin receptor type I, ACTR-I ACCESSION NO.: NP_001096 PROTEIN GI NO.: 4501895 GENE ID: 90 USER NOTE: Optimal dilutions for each application to be determined by the researcher.
  • Evolution, Expression and Meiotic Behavior of Genes Involved in Chromosome Segregation of Monotremes

    Evolution, Expression and Meiotic Behavior of Genes Involved in Chromosome Segregation of Monotremes

    G C A T T A C G G C A T genes Article Evolution, Expression and Meiotic Behavior of Genes Involved in Chromosome Segregation of Monotremes Filip Pajpach , Linda Shearwin-Whyatt and Frank Grützner * School of Biological Sciences, The University of Adelaide, Adelaide, SA 5005, Australia; fi[email protected] (F.P.); [email protected] (L.S.-W.) * Correspondence: [email protected] Abstract: Chromosome segregation at mitosis and meiosis is a highly dynamic and tightly regulated process that involves a large number of components. Due to the fundamental nature of chromosome segregation, many genes involved in this process are evolutionarily highly conserved, but duplica- tions and functional diversification has occurred in various lineages. In order to better understand the evolution of genes involved in chromosome segregation in mammals, we analyzed some of the key components in the basal mammalian lineage of egg-laying mammals. The chromosome passenger complex is a multiprotein complex central to chromosome segregation during both mitosis and meio- sis. It consists of survivin, borealin, inner centromere protein, and Aurora kinase B or C. We confirm the absence of Aurora kinase C in marsupials and show its absence in both platypus and echidna, which supports the current model of the evolution of Aurora kinases. High expression of AURKBC, an ancestor of AURKB and AURKC present in monotremes, suggests that this gene is performing all necessary meiotic functions in monotremes. Other genes of the chromosome passenger complex complex are present and conserved in monotremes, suggesting that their function has been preserved Citation: Pajpach, F.; in mammals.
  • Characterization of Pulmonary Arteriovenous Malformations in ACVRL1 Versus ENG Mutation Carriers in Hereditary Hemorrhagic Telangiectasia

    Characterization of Pulmonary Arteriovenous Malformations in ACVRL1 Versus ENG Mutation Carriers in Hereditary Hemorrhagic Telangiectasia

    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia Weiyi Mu, ScM1, Zachary A. Cordner, MD, PhD2, Kevin Yuqi Wang, MD3, Kate Reed, MPH, ScM4, Gina Robinson, RN5, Sally Mitchell, MD5 and Doris Lin, MD, PhD5 Purpose: Pulmonary arteriovenous malformations (pAVMs) are mutation carriers to have pAVMs (P o 0.001) or multiple lesions major contributors to morbidity and mortality in hereditary (P = 0.03), and to undergo procedural intervention (P = 0.02). hemorrhagic telangiectasia (HHT). Mutations in ENG and ACVRL1 Additionally, pAVMs in ENG carriers were more likely to exhibit underlie the vast majority of clinically diagnosed cases. The aims of bilateral lung involvement and growth over time, although this did this study were to characterize and compare the clinical and not reach statistical significance. The HHT severity score was morphologic features of pAVMs between these two genotype significantly higher in ENG than in ACVRL1 (P = 0.02). groups. Conclusion: The propensity and multiplicity of ENG-associated Methods: Sixty-six patients with HHT and affected family pAVMs may contribute to the higher disease severity in this members were included. Genotype, phenotypic data, and imaging genotype, as reflected by the HHT severity score and the frequency were obtained from medical records. Morphologic features of of interventional procedures. pAVMs were analyzed using computed tomography angiography. Genet Med HHT symptoms, pAVM imaging characteristics, frequency of advance online publication 19 October 2017 procedural intervention, and HHT severity scores were compared Key Words: ACVRL1; ENG; genotype-phenotype correlation; between ENG and ACVRL1 genotype groups.
  • Investigating the Role of Cdk11in Animal Cytokinesis

    Investigating the Role of Cdk11in Animal Cytokinesis

    Investigating the Role of CDK11 in Animal Cytokinesis by Thomas Clifford Panagiotou A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Molecular Genetics University of Toronto © Copyright by Thomas Clifford Panagiotou (2020) Investigating the Role of CDK11 in Animal Cytokinesis Thomas Clifford Panagiotou Master of Science Department of Molecular Genetics University of Toronto 2020 Abstract Finely tuned spatio-temporal regulation of cell division is required for genome stability. Cytokinesis constitutes the final stages of cell division, from chromosome segregation to the physical separation of cells, abscission. Abscission is tightly regulated to ensure it occurs after earlier cytokinetic events, like the maturation of the stem body, the regulatory platform for abscission. Active Aurora B kinase enforces the abscission checkpoint, which blocks abscission until chromosomes have been cleared from the cytokinetic machinery. Currently, it is unclear how this checkpoint is overcome. Here, I demonstrate that the cyclin-dependent kinase CDK11 is required for cytokinesis. Both inhibition and depletion of CDK11 block abscission. Furthermore, the mitosis-specific CDK11p58 kinase localizes to the stem body, where its kinase activity rescues the defects of CDK11 depletion and inhibition. These results suggest a model whereby CDK11p58 antagonizes Aurora B kinase to overcome the abscission checkpoint to allow for successful completion of cytokinesis. ii Acknowledgments I am very grateful for the support of my family and friends throughout my studies. I would also like to express my deep gratitude to Wilde Lab members, both past and present, for their advice and collaboration. In particular, I am very grateful to Matthew Renshaw, whose work comprises part of this thesis.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Casein Kinase 1 Isoforms in Degenerative Disorders

    Casein Kinase 1 Isoforms in Degenerative Disorders

    CASEIN KINASE 1 ISOFORMS IN DEGENERATIVE DISORDERS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Theresa Joseph Kannanayakal, M.Sc., M.S. * * * * * The Ohio State University 2004 Dissertation Committee: Approved by Professor Jeff A. Kuret, Adviser Professor John D. Oberdick Professor Dale D. Vandre Adviser Professor Mike X. Zhu Biophysics Graduate Program ABSTRACT Casein Kinase 1 (CK1) enzyme is one of the largest family of Serine/Threonine protein kinases. CK1 has a wide distribution spanning many eukaryotic families. In cells, its kinase activity has been found in various sub-cellular compartments enabling it to phosphorylate many proteins involved in cellular maintenance and disease pathogenesis. Tau is one such substrate whose hyperphosphorylation results in degeneration of neurons in Alzheimer’s disease (AD). AD is a slow neuroprogessive disorder histopathologically characterized by Granulovacuolar degeneration bodies (GVBs) and intraneuronal accumulation of tau in Neurofibrillary Tangles (NFTs). The level of CK1 isoforms, CK1α, CK1δ and CK1ε has been shown to be elevated in AD. Previous studies of the correlation of CK1δ with lesions had demonstrated its importance in tau hyperphosphorylation. Hence we investigated distribution of CK1α and CK1ε with the lesions to understand if they would play role in tau hyperphosphorylation similar to CK1δ. The kinase results were also compared with lesion correlation studies of peptidyl cis/trans prolyl isomerase (Pin1) and caspase-3. Our results showed that among the enzymes investigated, CK1 isoforms have the greatest extent of colocalization with the lesions. We have also investigated the distribution of CK1α with different stages of NFTs that follow AD progression.
  • Supplementary Information Material and Methods

    Supplementary Information Material and Methods

    MCT-11-0474 BKM120: a potent and specific pan-PI3K inhibitor Supplementary Information Material and methods Chemicals The EGFR inhibitor NVP-AEE788 (Novartis), the Jak inhibitor I (Merck Calbiochem, #420099) and anisomycin (Alomone labs, # A-520) were prepared as 50 mM stock solutions in 100% DMSO. Doxorubicin (Adriablastin, Pfizer), EGF (Sigma Ref: E9644), PDGF (Sigma, Ref: P4306) and IL-4 (Sigma, Ref: I-4269) stock solutions were prepared as recommended by the manufacturer. For in vivo administration: Temodal (20 mg Temozolomide capsules, Essex Chemie AG, Luzern) was dissolved in 4 mL KZI/glucose (20/80, vol/vol); Taxotere was bought as 40 mg/mL solution (Sanofi Aventis, France), and prepared in KZI/glucose. Antibodies The primary antibodies used were as follows: anti-S473P-Akt (#9271), anti-T308P-Akt (#9276,), anti-S9P-GSK3β (#9336), anti-T389P-p70S6K (#9205), anti-YP/TP-Erk1/2 (#9101), anti-YP/TP-p38 (#9215), anti-YP/TP-JNK1/2 (#9101), anti-Y751P-PDGFR (#3161), anti- p21Cip1/Waf1 (#2946), anti-p27Kip1 (#2552) and anti-Ser15-p53 (#9284) antibodies were from Cell Signaling Technologies; anti-Akt (#05-591), anti-T32P-FKHRL1 (#06-952) and anti- PDGFR (#06-495) antibodies were from Upstate; anti-IGF-1R (#SC-713) and anti-EGFR (#SC-03) antibodies were from Santa Cruz; anti-GSK3α/β (#44610), anti-Y641P-Stat6 (#611566), anti-S1981P-ATM (#200-301), anti-T2609 DNA-PKcs (#GTX24194) and anti- 1 MCT-11-0474 BKM120: a potent and specific pan-PI3K inhibitor Y1316P-IGF-1R were from Bio-Source International, Becton-Dickinson, Rockland, GenTex and internal production, respectively. The 4G10 antibody was from Millipore (#05-321MG).
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short

    Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short

    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
  • Tumor Promoting Effect of BMP Signaling in Endometrial Cancer

    Tumor Promoting Effect of BMP Signaling in Endometrial Cancer

    International Journal of Molecular Sciences Article Tumor Promoting Effect of BMP Signaling in Endometrial Cancer Tomohiko Fukuda 1,* , Risa Fukuda 1, Kohei Miyazono 1,2,† and Carl-Henrik Heldin 1,*,† 1 Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Box 582, Uppsala University, SE-751 23 Uppsala, Sweden; [email protected] (R.F.); [email protected] (K.M.) 2 Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan * Correspondence: [email protected] (T.F.); [email protected] (C.-H.H.); Tel.: +46-18-4714738 (T.F.); +46-18-4714738 (C.-H.H.) † These authors contributed equally to this work. Abstract: The effects of bone morphogenetic proteins (BMPs), members of the transforming growth factor-β (TGF-β) family, in endometrial cancer (EC) have yet to be determined. In this study, we analyzed the TCGA and MSK-IMPACT datasets and investigated the effects of BMP2 and of TWSG1, a BMP antagonist, on Ishikawa EC cells. Frequent ACVR1 mutations and high mRNA expressions of BMP ligands and receptors were observed in EC patients of the TCGA and MSK-IMPACT datasets. Ishikawa cells secreted higher amounts of BMP2 compared with ovarian cancer cell lines. Exogenous BMP2 stimulation enhanced EC cell sphere formation via c-KIT induction. BMP2 also induced EMT of EC cells, and promoted migration by induction of SLUG. The BMP receptor kinase inhibitor LDN193189 augmented the growth inhibitory effects of carboplatin. Analyses of mRNAs of several BMP antagonists revealed that TWSG1 mRNA was abundantly expressed in Ishikawa cells.
  • Multi-Modal Meta-Analysis of 1494 Hepatocellular Carcinoma Samples Reveals

    Multi-Modal Meta-Analysis of 1494 Hepatocellular Carcinoma Samples Reveals

    Author Manuscript Published OnlineFirst on September 21, 2018; DOI: 10.1158/1078-0432.CCR-18-0088 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Multi-modal meta-analysis of 1494 hepatocellular carcinoma samples reveals significant impact of consensus driver genes on phenotypes Kumardeep Chaudhary1, Olivier B Poirion1, Liangqun Lu1,2, Sijia Huang1,2, Travers Ching1,2, Lana X Garmire1,2,3* 1Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA 2Molecular Biosciences and Bioengineering Graduate Program, University of Hawaii at Manoa, Honolulu, HI 96822, USA 3Current affiliation: Department of Computational Medicine and Bioinformatics, Building 520, 1600 Huron Parkway, Ann Arbor, MI 48109 Short Title: Impact of consensus driver genes in hepatocellular carcinoma * To whom correspondence should be addressed. Lana X. Garmire, Department of Computational Medicine and Bioinformatics Medical School, University of Michigan Building 520, 1600 Huron Parkway Ann Arbor-48109, MI, USA, Phone: +1-(734) 615-5510 Current email address: [email protected] Grant Support: This research was supported by grants K01ES025434 awarded by NIEHS through funds provided by the trans-NIH Big Data to Knowledge (BD2K) initiative (http://datascience.nih.gov/bd2k), P20 COBRE GM103457 awarded by NIH/NIGMS, NICHD R01 HD084633 and NLM R01LM012373 and Hawaii Community Foundation Medical Research Grant 14ADVC-64566 to Lana X Garmire. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 21, 2018; DOI: 10.1158/1078-0432.CCR-18-0088 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
  • Human Kinome Profiling Identifies a Requirement for AMP-Activated

    Human Kinome Profiling Identifies a Requirement for AMP-Activated

    Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection Laura J. Terrya, Livia Vastagb,1, Joshua D. Rabinowitzb, and Thomas Shenka,2 aDepartment of Molecular Biology and bDepartment of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544 Contributed by Thomas Shenk, January 11, 2012 (sent for review December 29, 2011) Human cytomegalovirus (HCMV) modulates numerous cellular (7). Thus, the connections between AMPK activity and metabolic signaling pathways. Alterations in signaling are evident from the changes during HCMV infection have remained unclear. broad changes in cellular phosphorylation that occur during HCMV We confirmed the requirement for AMPK during infection, infection and from the altered activity of multiple kinases. Here we and we show that an AMPK antagonist, compound C, blocks report a comprehensive RNAi screen, which predicts that 106 cellular HCMV-induced changes to glycolysis and inhibits viral gene kinases influence growth of the virus, most of which were not expression. These studies argue that AMPK or a related, com- previously linked to HCMV replication. Multiple elements of the pound C-sensitive kinase is an essential contributor to metabolic AMP-activated protein kinase (AMPK) pathway scored in the screen. changes initiated by HCMV and provide unique insight into As a regulator of carbon and nucleotide metabolism, AMPK is poised potential antiviral strategies. to activate many of the metabolic pathways induced by HCMV infection. An AMPK inhibitor, compound C, blocked a substantial Results portion of HCMV-induced metabolic changes, inhibited the accumu- HumanKinomeScreenIdentifies Putative Effectors of HCMV Replication. lation of all HCMV proteins tested, and markedly reduced the We conducted an siRNA screen of the human kinome to perform an production of infectious progeny.